Acrivon Therapeutics (ACRV) News Today $1.28 -0.05 (-3.76%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.26 -0.02 (-1.17%) As of 07/15/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRV Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy RatingMay 21, 2025 | tipranks.comCantor Fitzgerald maintains Overweight on Acrivon Therapeutics stockMay 17, 2025 | uk.investing.comOppenheimer Sticks to Its Buy Rating for Acrivon Therapeutics, Inc. (ACRV)May 17, 2025 | theglobeandmail.comPiper Sandler Reaffirms Their Buy Rating on Acrivon Therapeutics, Inc. (ACRV)May 17, 2025 | theglobeandmail.comJones Trading Downgrades Acrivon Therapeutics (ACRV)May 17, 2025 | msn.comAcrivon Therapeutics downgraded to Hold from Buy at JonesResearchMay 17, 2025 | finance.yahoo.comAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 16, 2025 | finanznachrichten.deAcrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy RatingMay 15, 2025 | tipranks.comAcrivon Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 14, 2025 | globenewswire.comInsider Selling: Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Sells 437,881 Shares of StockMay 2, 2025 | insidertrades.comMajor Shareholder Sells Massive Stake in Acrivon Therapeutics!May 1, 2025 | tipranks.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Sells $335,841.48 in StockApril 30, 2025 | insidertrades.comMajor Shareholder Sells Millions in Acrivon Therapeutics Stock!April 29, 2025 | tipranks.comMarshall Wace LLP Sells 212,065 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV)April 28, 2025 | marketbeat.comAcrivon Therapeutics to present data from analyses of ACR-2316 at AACRApril 26, 2025 | markets.businessinsider.comAcrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025April 25, 2025 | globenewswire.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 21.4% in MarchApril 21, 2025 | marketbeat.comAcrivon appoints new chief medical officer to advance cancer trialsApril 9, 2025 | uk.investing.comAcrivon appoints Mansoor Raza Mirza as Chief Medical OfficerApril 9, 2025 | markets.businessinsider.comAcrivon Therapeutics Reports Progress in Cancer Drug DevelopmentApril 7, 2025 | tipranks.comAcrivon Therapeutics Appoints New Chief Medical OfficerApril 7, 2025 | tipranks.comAcrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical OfficerApril 7, 2025 | globenewswire.comWhat is HC Wainwright's Forecast for ACRV Q1 Earnings?March 29, 2025 | marketbeat.comAcrivon Therapeutics price target lowered to $10 from $18 at OppenheimerMarch 29, 2025 | markets.businessinsider.comAcrivon Therapeutics (NASDAQ:ACRV) Releases Earnings ResultsMarch 28, 2025 | marketbeat.comEquities Analysts Set Expectations for ACRV FY2029 EarningsMarch 28, 2025 | marketbeat.comAcrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial ResultsMarch 27, 2025 | globenewswire.comCantor Fitzgerald Reiterates "Overweight" Rating for Acrivon Therapeutics (NASDAQ:ACRV)March 27, 2025 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $19.00 by Analysts at HC WainwrightMarch 27, 2025 | marketbeat.comAcrivon Therapeutics: Promising Oncology Advancements and Strategic Positioning Justify Buy RatingMarch 23, 2025 | tipranks.comAcrivon Therapeutics (ACRV) to Release Quarterly Earnings on ThursdayMarch 20, 2025 | marketbeat.comAcrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program UpdatesMarch 19, 2025 | globenewswire.comAcrivon Therapeutics appoints new CFO as predecessor steps downMarch 16, 2025 | investing.comShort Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 33.7%March 15, 2025 | marketbeat.comAcrivon Therapeutics Appoints New Chief Financial OfficerMarch 14, 2025 | tipranks.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Recommendation of "Buy" from BrokeragesMarch 11, 2025 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest UpdateFebruary 18, 2025 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of "Buy" by AnalystsFebruary 14, 2025 | marketbeat.comAcrivon Therapeutics announces FDA granted BDD for ACR-368February 6, 2025 | markets.businessinsider.comAcrivon Therapeutics Stock Rises 14% On FDA Recognition For ACR-368 OncoSignature AssayFebruary 5, 2025 | markets.businessinsider.comAcrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough StatusFebruary 5, 2025 | msn.comAcrivon Therapeutics Gets FDA Breakthrough Device Designation for Cancer IdentificationFebruary 5, 2025 | marketwatch.comACR-368 OncoSignature assay gains FDA breakthrough statusFebruary 5, 2025 | msn.comAcrivon Therapeutics:FDA Grants Breakthrough Device Designation For ACR-368 OncoSignature AssayFebruary 5, 2025 | markets.businessinsider.comAcrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial CancerFebruary 5, 2025 | finance.yahoo.comBrokers Offer Predictions for ACRV FY2024 EarningsFebruary 5, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Acrivon Therapeutics (ACRV) with Overweight RecommendationFebruary 1, 2025 | msn.comCantor Fitzgerald sets Acrivon stock to Overweight on AP3 platformJanuary 31, 2025 | msn.comAcrivon Therapeutics initiated with an Overweight at Cantor FitzgeraldJanuary 31, 2025 | markets.businessinsider.comAcrivon Therapeutics, Inc. (ACRV) Initiated with a Buy at Cantor FitzgeraldJanuary 31, 2025 | markets.businessinsider.com Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRV Media Mentions By Week ACRV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRV News Sentiment▼1.870.97▲Average Medical News Sentiment ACRV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRV Articles This Week▼12▲ACRV Articles Average Week Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DiaMedica Therapeutics News Today Nuvectis Pharma News Today Compugen News Today Aclaris Therapeutics News Today Molecular Partners News Today Alector News Today Ventyx Biosciences News Today Lexeo Therapeutics News Today Theratechnologies News Today Black Diamond Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRV) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRV Stock Alerts